The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. check here While sharing a comparable therapeutic goal – improving glycemic control and promoting significant weight reduction – they exhibit intriguing